Published in final edited form as:

Cancer Res. 2010 September 15; 70(18): 7148–7154. doi:10.1158/0008-5472.CAN-10-1457.

Spontaneous tumorigenesis in mice overexpressing the p53 negative regulator Mdm4

Shunbin Xiong^{*}, Vinod Pant^{*}, Young-Ah Suh^{*}, Carolyn S. Van Pelt[†], Yongxing Wang^{*,‡}, Yasmine A. Valentin –Vega^{*,‡}, Sean M. Post, and Guillermina Lozano^{*,‡,§}

^{*} Department of Genetics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030

[†] Department of Veterinary Medicine and Surgery, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030

[‡] The University of Texas Graduate School in Biomedical Sciences and Program in Genes and Development

Abstract

High levels of the critical p53 inhibitor Mdm4 is common in tumors which retain a wild-type *p53* allele, suggesting that Mdm4 overexpression is an important mechanism for p53 inactivation during tumorigenesis. To test this hypothesis *in vivo*, we generated transgenic mice with widespread expression of Mdm4. Two independent lines of transgenic mice, *Mdm4^{Tg1}* and *Mdm4^{Tg15}* developed spontaneous tumors, the most prevalent of which were sarcomas. To determine whether overexpression of Mdm4 also cooperated with *p53* heterozygosity to induce tumorigenesis, we generated *Mdm4^{Tg1} p53^{+/-}* mice. These mice had significantly accelerated tumorigenesis and a distinct tumor spectrum with more carcinomas and significantly fewer lymphomas than *p53^{+/-}* or *Mdm4^{Tg1}* mice. Importantly, the remaining wild type *p53* allele was retained in most *Mdm4^{Tg1} p53^{+/-}* tumors. Mdm4 is thus a *bona fide* oncogene *in vivo*, and cooperates with *p53* heterozygosity to drive tumorigenesis. These *Mdm4* mice will be invaluable for *in vivo* drug studies of Mdm4 inhibitors.

Introduction

Inactivation of the p53 tumor suppressor is a critical step in tumorigenesis (1). *p53* is mutated or deleted in many human cancers. Other tumors with wild-type p53 have defects in critical regulators of p53, such as p14^{ARF} and Mdm2 (2). Mdm2 inhibits p53 transcriptional activity and mediates the degradation of p53 through its E3 ubiquitin ligase activity (3–5). Amplification of the *MDM2* gene occurs in 30–40% of human sarcomas and leukemias many of which retain wild-type *p53* (6–8). Also, high levels of MDM2 are found in many other tumors (9,10), and are associated with poor prognosis in patients with non-Hodgkin's lymphoma (11). In mice, overexpression of Mdm2 induces tumorigenesis in a wild-type *p53* background (12). These data demonstrate that Mdm2 is an oncogene *in vivo*.

Another potential mechanism for disrupting the p53 pathway in tumorigenesis is through Mdm4, an Mdm2 homologue that also inhibits p53 function (13,14). Mouse embryos lacking *Mdm4* die during embryogenesis; however, this phenotype is completely rescued by loss of *p53* (14–16). These data demonstrate that Mdm4 is a negative regulator of p53 that is

[§]To whom correspondence may be addressed, The University of Texas M. D. Anderson Cancer Center, Unit 1010, 1515 Holcombe Boulevard, Houston, TX 77030. Telephone: (713) 834-6386; Fax: (713) 834-6380; gglozano@mdanderson.org.

not redundant with Mdm2. Overexpression of Mdm4 with *HRas*^{v12} transforms mouse embryonic fibroblasts (MEFs) suggesting a role in transformation (17). Additionally, MDM4 is highly expressed in a significant percentage of human tumors including 65% of retinoblastomas (18), 39% of head and neck squamous carcinomas (10), 19% of breast cancers, 19% of colon cancers, 18% of lung cancers (17), and 80% of adult pre-B lymphoblastic leukemia (19). Most retinoblastomas, and head and neck squamous carcinomas have wild type *p53* (10,18). These studies strengthen the argument that *MDM4* is an oncogene.

Mdm4 also interacts with Mdm2 through its RING finger (20), which leads to its ubiquitination by Mdm2 and subsequent degradation by the 26S proteasome (21–23). DNA damage induces Mdm4 phosphorylation and subsequent ubiquitination and degradation, which is required for the *p53*-mediated DNA damage response (24–28). However, the role of Mdm4 overexpression in the *p53*-mediated DNA damage response *in vivo* is unclear.

To investigate the effects of Mdm4 overexpression *in vivo*, we generated transgenic *Mdm4* mice using two strategies. Since previous studies show high levels of Mdm2 cause embryonic lethality in mice (12), we reasoned that high levels of Mdm4 might also lead to developmental phenotypes. We therefore created a conditional transgenic mouse (*Mdm4*^{Tg}) in which the *Mdm4* transgene is expressed only upon deletion of a floxed enhanced green fluorescent protein (EGFP) cassette (*Mdm4*^{Tg1}). *Mdm4*^{Tg1} mice were viable and developed spontaneous tumors. Another transgenic line, *Mdm4*^{Tg15}, constitutively expressing Mdm4 also showed a cancer phenotype. Lastly, *Mdm4*^{Tg1} *p53*^{+/-} mice showed significantly accelerated tumorigenesis with retention of wild type *p53* in most tumors. Mdm4 overexpression also contributed to reduced *p53* stability in response to stress. These transgenic *Mdm4* mouse models show a direct role of Mdm4 overexpression in tumorigenesis *in vivo*, and serve as important models for drug screening and cancer therapy.

Material and Methods

Generation of Transgenic Mdm4 Mice

The transgenic *Mdm4* mice were generated by pronuclear injection at The University of Texas M. D. Anderson Cancer Center Genetically Engineered Mouse Facility. The transgene was identified by PCR using primers: ALF, AGGGCGGGTTCGGCTTCTGG and E4re, TCCCAAAGATCTCCACCACAGTA. To delete *EGFP*, *Mdm4*^{Tg} mice were mated with *Zp3-Cre* mice, and then with C57Bl/6J mice to generate *Mdm4*^{Tg1} mice.

Western Blot Analysis

Protein lysates prepared from HeLa and HepG2 cells, MEFs, tissues, and tumors were used for western blots. HeLa and HepG2 cells were originally obtained from ATCC in 2005, and aliquots were subsequently frozen in liquid nitrogen until time of use. The cells were cultured in Eagle's Minimum Essential media supplemented with 10% fetal bovine serum as per ATCC recommendations. HeLa and HepG2 cells were authenticated by G-banded karyotyping analysis on 7/7/2010 by MD Anderson Cytogenetics Core Facility. Early passage MEFs generated from 13.5 day post coitum embryos and cultured in DMEM supplemented with 10% fetal bovine serum were used for the analysis. In radiation experiments, 6–8 week-old wild-type and transgenic mice were irradiated at 6 Gy and then sacrificed at different time points. Antibodies used for western blots were: *p53* (CM5, Novacastra, MA); *p21* (BD Biosciences, NJ); cleaved-caspase 3 (Cell Signaling, MA); Mdm4 antibody (MX82); actin, (Santa Cruz biotechnology Inc); vinculin, β -actin, and tubulin (Sigma, MO); Mdm2 (2A10) (Calbiochem, NJ).

Real Time quantitative PCR

Splenocytes were isolated by mashing spleens between the rough part of superfrost slides (Fisher Scientific) and suspended in warm RPMI media (10% Fetal Bovine serum). The cell mixture was then passed through a nylon fiber-filled mini-column (Wako, Japan). The cells were spun down and suspended in 5ml RBC lysis buffer (eBioscience) for 5 minutes. Total RNA was isolated from splenocytes, tissues, and MEFs using Trizol reagent (Invitrogen, CA), and then treated with DNase. cDNAs were made using first strand reverse transcriptase kit (GE Healthcare, UK). The *p21*, *Mdm2*, *Puma* and *Gapdh* primers were previously described (29). *Mdm4* primers for RT-qPCR are: GGAAAAGCCCAGGTTTGACC; and GCCAAATCCAAAAATCCCACT.

LOH of p53 Allele Assay

Tumor DNA was digested with EcoRI and StuI, following a published protocol (30).

Statistical Analysis

Student's t test and Kaplan-Meier survival analysis were performed using Prism 4 software (GraphPad Software, CA). Differences were considered significant at $P < 0.05$.

Results

Transgenic mice express varying levels of Mdm4

To prevent the potential toxic effects of Mdm4 overexpression on embryonic development, we first generated a conditional mouse model for Mdm4 overexpression. The *Mdm4* transgene is driven by the cytomegalovirus (CMV) immediate-early (IE) enhancer, and the chicken β -actin promoter with an intron that drives widespread expression of genes in a number of transgenic models (31). The construct also contained *EGFP* flanked by loxP sites followed by the *Mdm4* cDNA, an internal ribosome entry site (IRES), the *lacZ* gene and an SV40 polyA sequence (Figure 1). Using this conditional strategy, the entire transgene will be transcribed, and *EGFP* and *lacZ* will be translated into protein. Deletion of *EGFP* allows translation of *Mdm4* and *lacZ*. Transgenic mice were generated and crossed to C57Bl/6J mice. Embryos were screened by whole-mount X-gal staining at embryonic day 13.5. We identified one transgenic line with intense and extensive X-gal staining (referred to as *Mdm4^{Tg}*) (Supplemental Figure S1A). These mice were subsequently crossed with *Zp3-Cre* mice (also in a C57Bl/6J background) to delete the *EGFP* cassette in female germ cells (32), and crossed once again to C57Bl/6J mice to generate *Mdm4^{Tg1}* mice that were >87% C57Bl/6J. Detailed analysis of *Mdm4^{Tg1}* mice showed positive X-gal staining in the retina on postnatal day 2, and in the heart, kidney, and uterus at 2 months of age (Supplemental Figure S1B and 1C) suggesting that overexpression of the transgene continues throughout the mouse's life span. In 2 month-old mice, expression of Mdm4 was also determined by real time (RT)-qPCR and western blotting in multiple organs. The heart, muscle, and intestine showed significantly higher expression of Mdm4 than wild type controls (Table 1 and Figure S1D).

Since Mdm4 transgenic mice did not have obvious developmental defects, we subsequently used a constitutive strategy to drive Mdm4 overexpression (Figure 1B). We obtained two additional transgenic mouse lines, *Mdm4^{Tg6}* and *Mdm4^{Tg15}*. RT-qPCR showed that both lines also had widespread expression of *Mdm4* in mouse embryo fibroblasts (MEFs), spleen, thymus, lung, intestine, heart, muscle, liver (*Mdm4^{Tg15}* only), and kidney (*Mdm4^{Tg15}* only) (Figure 2A and Table 1). Western blot analysis of MEFs, spleen, heart, and brain tissues showed high levels of Mdm4 protein as well (Figure 2B and 2C). Mdm4 protein was not detectable in wild type spleen and heart tissues, and is barely visible in brain (data not shown). In general, expression of Mdm4 was higher in *Mdm4^{Tg6}* and *Mdm4^{Tg15}* MEFs and

tissues than in *Mdm4^{Tg1}* samples (Figure 2). Western blots for Mdm2 and p53 were also performed and show undetectable levels of these proteins. All three transgenic lines contain a single copy of the transgene (Supplemental Figure S1E).

Spontaneous tumorigenesis in *Mdm4* transgenic mice

We monitored spontaneous tumorigenesis in *Mdm4^{Tg1}* mice, and observed that these mice developed tumors earlier than control *Mdm4^{Tg}* mice with the *EGFP* transgene which did not express *Mdm4* yet had the same integration site (Figure 3). *Mdm4^{Tg1}* mice developed a variety of tumors and died significantly faster than control *Mdm4^{Tg}* mice ($P < 0.004$) (Figure 3A). Twenty-six percent of the *Mdm4^{Tg1}* mice (20/75) had tumors during the 18-month observation period, and 20% of these had more than one type of tumor. Tumor types observed were sarcomas (38%), lymphomas (33%), histiocytic sarcoma of macrophage origin (17%) (Figure 3B) and carcinomas (13%) (Table 2). One osteosarcoma metastasized to the lung (Table 2; Figure 3B and Supplemental Table 1). Mdm4 levels were higher in tumors as compared to normal tissues; for example, lymphoma vs normal thymus and sarcoma vs normal muscle (Figure 3C and Supplemental Figure 2). Six tumors which were well separated from the surrounding normal tissues had high levels of Mdm4 and Mdm2 by western blot analyses (Figure 3C). p53 was also high in five of six tumors (Figure 3C). The sequences of p53 cDNAs cloned from these six tumors were all wild type for p53. Additional studies of a second transgenic mouse line, *Mdm4^{Tg15}* (75% C57Bl/6J), also showed that these mice had shortened life spans and developed spontaneous tumors ($P < 0.0001$ as compared to *Mdm4^{Tg}* mice). *Mdm4^{Tg15}* mice developed 31% histiocytic sarcomas (including 2 metastases), 31% sarcomas (one tumor had metastasis to the spleen), 31% lymphomas, and 7% carcinomas. Four of eleven mice developed more than one type of tumor (Supplemental Table 1). Preliminary data from *Mdm4^{Tg6}* mice (3/29) indicated development of lymphomas and adenomas. Mdm4 protein levels were high in 5 of 7 *Mdm4^{Tg15}* tumors and both *Mdm4^{Tg6}* tumors by western blot analysis (Figure 3D). For comparison, protein lysates from HeLa, and HepG2 human tumor cell lines also showed high levels of Mdm4. These data indicated that overexpression of Mdm4 contributed to a tumor phenotype in mice.

Tumors develop in *p53* heterozygous mice at a modest rate resembling human cases of Li-Fraumeni syndrome (30,33). In approximately half of these tumors, loss of one *p53* allele is associated with loss of the second *p53* allele. Tumors retaining wild type *p53* likely acquire other changes to inactivate the pathway (30,34). To test the hypothesis that Mdm4 overexpression cooperates with *p53* heterozygosity to promote tumorigenesis, we crossed *Mdm4^{Tg1}* mice with *p53* heterozygous mice (also in a C57Bl/6J background), and monitored spontaneous tumorigenesis. The median survival for the *Mdm4^{Tg1} p53^{+/-}* mice was 388 days, which was significantly shorter than *Mdm4^{Tg1}* littermates in which <50% of the mice died during 18 months of observation, and *p53^{+/-}* mice (578 days ($P < 0.0001$)) (Figure 4A). The *Mdm4^{Tg1} p53^{+/-}* mice however lived longer than the *p53^{-/-}* mice (median survival 160 days) (Figure 4A). Additionally, 11% of the tumors (5/44) in *Mdm4^{Tg1} p53^{+/-}* mice were carcinomas, which was higher than the percentage of carcinomas in *p53^{+/-}* littermates (5%). Conversely, the percentage of double-mutant mice with lymphomas (11%) was significantly lower than that of the *p53^{+/-}* mice (23%; $P < 0.02$) (Table 2). Interestingly, one *Mdm4^{Tg1} p53^{+/-}* mouse had a neurofibrosarcoma, which has not been reported in *p53^{+/-}* mice (Table 2). Western blot analysis of tumor lysates from *Mdm4^{Tg1} p53^{+/-}* indicated that 11 of 13 tumors had high levels of Mdm4 (Figure 4B). We also selected 13 very well isolated tumors including 7 osteosarcomas to perform Southern blot analysis to determine whether these tumors had *p53* loss of heterozygosity (LOH). Strikingly, only one of thirteen tumors showed *p53* LOH (Figure 4C) compared to *p53^{+/-}* mice in which approximately half of the tumors show LOH (30,34). We also sequenced *p53*

from 7 tumors, 6 of which were wild type for *p53*. One tumor had a Val to Ala substitution at *p53* amino acid 213 which is not one of the known loss-of-function mutations. These data suggest that overexpression of Mdm4 reduced the selective pressure for inactivating the wild type *p53* allele in *Mdm4^{Tg1} p53^{+/-}* tumors.

Overexpression of Mdm4 dampened *p53* response after IR

The generation of mice with high levels of Mdm4 offered the opportunity to examine the effect on *p53* mediated DNA damage response *in vivo*. To examine the effects of Mdm4 overexpression after DNA damage *in vivo*, we irradiated *Mdm4^{Tg15}* female mice. After IR, Mdm4 protein levels decreased in spleens of *Mdm4^{Tg15}* mice consistent with previous *in vitro* data (23,28) (Figure 5A). Additionally, *p53* was stabilized to a much lower extent in spleen samples of these transgenic mice than in wild-type littermates (Figure 5A and Figure S2). RT-qPCR experiments for activation of *p53* downstream target genes showed *Mdm2*, *p21*, and *Puma* mRNA levels (35,36) were induced to a lesser extent than in wild-type littermates after IR in splenocytes (Figure 5B). These data suggested that *Mdm4* transgenic mice exhibit a dampened *p53* response after IR.

Discussion

We generated transgenic mice with widespread expression of Mdm4. All transgenic lines with Mdm4 overexpression were viable and did not show obvious developmental defects. The two transgenic lines *Mdm4^{Tg1}* and *Mdm4^{Tg15}* examined developed spontaneous tumors (Table 2). This is direct evidence that Mdm4 is a *bona fide* oncogene that induces tumorigenesis *in vivo*. While *Mdm4^{Tg1}* tumors had high levels of Mdm4, they also had high levels of Mdm2 and *p53*. High Mdm2 levels are incompatible with *p53* stability as Mdm2 is an E3 ubiquitin ligase for *p53*. Mdm4 cannot degrade *p53* but can block Mdm2 access to *p53* as they bind the same domain of *p53* with similar affinities (37). Notably, Mdm4 overexpression in normal adult tissues in *Mdm4^{Tg1}* mice is patchy, but expression of Mdm4 in tumors was high, suggesting tumors arose from Mdm4 overexpressing cells.

The *p53*-mediated DNA damage response was also dampened in Mdm4 overexpressing cells. After IR treatment, while Mdm4 levels in *Mdm4^{Tg15}* mice decreased with time (probably as a cellular response to activate *p53*), it remained higher than normal at early time points and suppressed transcription of *Mdm2*, *p21*, and *Puma* in splenocytes. Compared to wild type mice, mice overexpressing Mdm4 also showed reduced *p53* stabilization after IR. These data are consistent with recently published data that show degradation of Mdm4 after IR is crucial for *p53*-mediated radiation response (28). High Mdm4 levels may delay the phosphorylation of *p53* and therefore hinder *p53* stabilization and activation after IR. Since the level of Mdm4 protein affects the radiation response, it may also affect the outcome of radiotherapy in cancer patients.

The median survival of *Mdm4^{Tg1} p53^{+/-}* mice at 388 days was significantly shorter than that of *p53^{+/-}* mice at 578 days. *Mdm4^{Tg1} p53^{+/-}* mice also had significantly decreased lymphoma incidence and increased carcinoma incidence compared to *p53^{+/-}* mice alone. These data indicate that Mdm4 overexpression not only cooperated with *p53* heterozygosity to accelerate tumorigenesis but also altered tumor spectra. More importantly, Mdm4 overexpression in *p53^{+/-}* mice allowed retention of wild type *p53* in most tumors suggesting that overexpression of Mdm4 reduced the selective pressure to inactivate the wild type *p53* allele.

Because blocking the inhibitory effects of Mdm4 is a clear therapeutic strategy for cancers with high Mdm4 levels and wild type *p53* (38), our Mdm4 transgenic mice will be invaluable for testing the efficacy of Mdm4 inhibitors *in vivo*. Since human retinoblastomas

express high levels of MDM4 and *Mdm4^{Tg1}* mice overexpress Mdm4 in the retina, it may be a great model to study the progression of the disease upon inactivation of other members of the Rb pathway (18). Also overexpression of Mdm4 inhibits the therapeutic effect of the Mdm2 inhibitor Nutlin3 (39,40), indicating that this mouse model can also be useful to examine how overexpression of Mdm4 affects the efficacy of Mdm2 inhibitors.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Drs. Parant, and Jackson for helpful discussions. We thank Ana C. Elizondo-Fraire for technical assistance. This work was supported by an institutional research grant and the Center for Targeted Therapy Disease-Specific Grant Program from M. D. Anderson Cancer Center (to SX) and NIH grant CA47296 (to GL).

Abbreviations

MEFs	mouse embryonic fibroblasts
IE	Immediate Early
LOH	Loss of heterozygosity
IR	ionizing radiation
Gy	Gray

References

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. *Nature*. 2000; 408:307–10. [PubMed: 11099028]
2. Attardi LD, Jacks T. The role of p53 in tumour suppression: lessons from mouse models. *Cellular & Molecular Life Sciences*. 1999; 55:48–63. [PubMed: 10065151]
3. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. *Nature*. 1997; 387:296–9. [PubMed: 9153395]
4. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. *FEBS Lett*. 1997; 420:25–7. [PubMed: 9450543]
5. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. *Nature*. 1997; 387:299–303. [PubMed: 9153396]
6. Iwakuma T, Lozano G. MDM2, an introduction. *Molecular Cancer Research: MCR*. 2003; 1:993–1000. [PubMed: 14707282]
7. Watanabe T, Hotta T, Ichikawa A, et al. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. *Blood*. 1994; 84:3158–65. [PubMed: 7949188]
8. Zhou M, Yeager AM, Smith SD, Findley HW. Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. *Blood*. 1995; 85:1608–14. [PubMed: 7888679]
9. Evans SC, Viswanathan M, Grier JD, Narayana M, El-Naggar AK, Lozano G. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. *Oncogene*. 2001; 20:4041–9. [PubMed: 11494132]
10. Valentin-Vega YA, Barboza JA, Chau GP, El-Naggar AK, Lozano G. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. *Hum Pathol*. 2007; 38:1553–62. [PubMed: 17651783]

11. Moller MB, Nielsen O, Pedersen NT. Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities. *Mod Pathol.* 1999; 12:1010–6. [PubMed: 10574597]
12. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. *Proc Natl Acad Sci U S A.* 1998; 95:15608–12. [PubMed: 9861017]
13. Shvarts A, Steegenga WT, Riteco N, et al. MDMX: a novel p53-binding protein with some functional properties of MDM2. *Embo J.* 1996; 15:5349–57. [PubMed: 8895579]
14. Migliorini D, Denchi EL, Danovi D, et al. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. *Mol Cell Biol.* 2002; 22:5527–38. [PubMed: 12101245]
15. Parant J, Chavez-Reyes A, Little NA, et al. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. *Nat Genet.* 2001; 29:92–5. [PubMed: 11528400]
16. Finch RA, Donoviel DB, Potter D, et al. mdmx is a negative regulator of p53 activity in vivo. *Cancer Res.* 2002; 62:3221–5. [PubMed: 12036937]
17. Danovi D, Meulmeester E, Pasini D, et al. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. *Mol Cell Biol.* 2004; 24:5835–43. [PubMed: 15199139]
18. Laurie NA, Donovan SL, Shih CS, et al. Inactivation of the p53 pathway in retinoblastoma. *Nature.* 2006; 444:61–6. [PubMed: 17080083]
19. Han X, Garcia-Manero G, McDonnell TJ, et al. HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. *Mod Pathol.* 2007; 20:54–62. [PubMed: 17143258]
20. Marine JC, Jochemsen AG. Mdmx and Mdm2: brothers in arms? *Cell Cycle.* 2004; 3:900–4. [PubMed: 15254433]
21. Pan Y, Chen J. MDM2 promotes ubiquitination and degradation of MDMX. *Mol Cell Biol.* 2003; 23:5113–21. [PubMed: 12860999]
22. de Graaf P, Little NA, Ramos YF, Meulmeester E, Letteboer SJ, Jochemsen AG. Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2. *J Biol Chem.* 2003; 278:38315–24. [PubMed: 12874296]
23. Kawai H, Wiederschain D, Kitao H, Stuart J, Tsai KK, Yuan ZM. DNA damage-induced MDMX degradation is mediated by MDM2. *J Biol Chem.* 2003; 278:45946–53. [PubMed: 12963717]
24. Chen L, Gilkes DM, Pan Y, Lane WS, Chen J. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. *Embo J.* 2005; 24:3411–22. [PubMed: 16163388]
25. Pereg Y, Shkedy D, de Graaf P, et al. Phosphorylation of Hdmx mediates its Mdm2- and ATM-dependent degradation in response to DNA damage. *Proc Natl Acad Sci U S A.* 2005; 102:5056–61. [PubMed: 15788536]
26. Okamoto K, Kashima K, Pereg Y, et al. DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. *Mol Cell Biol.* 2005; 25:9608–20. [PubMed: 16227609]
27. Jin Y, Dai MS, Lu SZ, et al. 14-3-3gamma binds to MDMX that is phosphorylated by UV-activated Chk1, resulting in p53 activation. *Embo J.* 2006; 25:1207–18. [PubMed: 16511572]
28. Wang YV, Leblanc M, Wade M, Jochemsen AG, Wahl GM. Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases. *Cancer Cell.* 2009; 16:33–43. [PubMed: 19573810]
29. Xiong S, Van Pelt CS, Elizondo-Fraire AC, Liu G, Lozano G. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. *Proc Natl Acad Sci U S A.* 2006; 103:3226–31. [PubMed: 16492743]
30. Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. *Current Biology.* 1994; 4:1–7. [PubMed: 7922305]
31. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. *Gene.* 1991; 108:193–9. [PubMed: 1660837]

32. Lewandoski M, Wassarman KM, Martin GR. Zp3-cre, a transgenic mouse line for the activation or inactivation of loxP-flanked target genes specifically in the female germ line. *Current Biology*. 1997; 7:148–51. [PubMed: 9016703]
33. Donehower LA, Godley LA, Aldaz CM, et al. Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. *Genes Dev*. 1995; 9:882–95. [PubMed: 7705663]
34. Venkatachalam S, Shi YP, Jones SN, et al. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. *Embo J*. 1998; 17:4657–67. [PubMed: 9707425]
35. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. *Mol Cell*. 2001; 7:683–94. [PubMed: 11463392]
36. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. *Mol Cell*. 2001; 7:673–82. [PubMed: 11463391]
37. Bottger V, Bottger A, Garcia-Echeverria C, et al. Comparative study of the p53- mdm2 and p53-MDMX interfaces. *Oncogene*. 1999; 18:189–99. [PubMed: 9926934]
38. Wade M, Wahl GM. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? *Mol Cancer Res*. 2009; 7:1–11. [PubMed: 19147532]
39. Hu B, Gilkes DM, Farooqi B, Sebt SM, Chen J. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. *J Biol Chem*. 2006; 281:33030–5. [PubMed: 16905541]
40. Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. *Cancer Res*. 2006; 66:3169–76. [PubMed: 16540668]

A. Mdm4 conditional transgene

B. Mdm4 constitutive transgene

Figure 1.

Generation of Mdm4 transgenic mice. (A) The chicken β-actin promoter and intron with a cytomegalovirus (CMV) immediate-early (IE) enhancer drive expression of the *Mdm4* cDNA upon deletion of *EGFP* which is flanked by loxP sites. An internal ribosomal entry site allows *LacZ* expression. A rabbit β-globin polyadenylation signal (poly A) was placed at the 3' end. ALF and E4 mark the location of primers for genotyping. (B) A constitutive *Mdm4* transgene driven by the chicken β-actin promoter and CMV IE enhancer was used to generate *Mdm4^{Tg6}* and *Mdm4^{Tg15}* lines.

Figure 2.

Mdm4 overexpression in mouse tissues of different transgenic lines. (A) *Mdm4* mRNA levels in MEFs from *Mdm4^{Tg1}*, *Mdm4^{Tg6}* and *Mdm4^{Tg15}* lines were determined by RT-qPCR and plotted as fold change compared to *Gapdh* with wild type (WT) control set to 1. Three different MEF lines were analyzed for each genotype (p values were calculated by student *t*-test). (B) Mdm4 protein levels in MEFs from different lines were assayed by western blotting. se, short exposure; le, long exposure. (C) Western blots from various tissues of 2-month-old transgenic *Mdm4^{Tg}*, *Mdm4^{Tg1}*, *Mdm4^{Tg6}*, and *Mdm4^{Tg15}* mice using an Mdm4 antibody. β -Actin antibodies were used to determine equal loading of the same blot except for heart (H) as that blot was run longer to eliminate overlap with a non-specific band. Sp, Spleen; Br, Brain; DN, protein lysate from double null (*Mdm4^{-/-} p53^{-/-}*) cells; TN, protein lysate from triple null (*Mdm2^{-/-} Mdm4^{-/-} p53^{-/-}*) cells; P: protein lysate from *Mdm4^{Tg6}* MEFs as positive control.

Figure 3.

Spontaneous tumorigenesis in *Mdm4^{Tg1}* and *Mdm4^{Tg15}* Mice. (A) Kaplan-Meier survival curves for *Mdm4^{Tg}*, *Mdm4^{Tg1}* and *Mdm4^{Tg15}* mice. (B) Hematoxylin and eosin staining of spontaneous tumors from *Mdm4^{Tg1}* mice: histiocytic sarcoma (20x), and a metastatic osteosarcoma to the lung (10x). (C) Western blots from *Mdm4^{Tg1}* tumors and normal tissues using Mdm4, p53, and Mdm2 antibodies. β -actin and vinculin antibodies were used as a control for loading. T, Thymus; M, Muscle; HS, Histiocytic sarcoma; Ly, Lymphoma; OS, Osteosarcoma; SN, Sarcoma, not otherwise specified. (D) Western blot analysis of *Mdm4^{Tg6}* and *Mdm4^{Tg15}* tumors, HepG2, and HeLa human tumor cell lines for comparison. Asterisk marks human MDM4 and arrowhead marks murine Mdm4 proteins. TN, protein lysate from

triple null (*Mdm2*^{-/-} *Mdm4*^{-/-} *p53*^{-/-}) cells; P: protein lysate from *Mdm4*^{Tg6} MEFs as positive control.

Figure 4.

Acceleration of tumorigenesis in *p53^{+/-}* mice by overexpression of Mdm4. (A) Kaplan-Meier survival curves for *Mdm4^{Tg1}*, *p53^{+/-}*, *Mdm4^{Tg1} p53^{+/-}*, and *p53^{-/-}* mice. (B) Western blots of *Mdm4^{Tg1}p53^{+/-}* tumor lysates using Mdm4 and vinculin antibodies. The first lane is a *Mdm4^{-/-}p53^{-/-}* MEF control. (C) Southern blot analysis of *Mdm4^{Tg1} p53^{+/-}* tumor DNA samples. The asterisk denotes sample with LOH. HS, Histiocytic sarcoma; OS, osteosarcoma; Ly, lymphoma; NF, Neurofibrosarcoma; SN, Sarcoma, not otherwise specified; AC, Mammary Adenocarcinoma; ψ, p53 pseudogene. *p53* homozygous (+/+), heterozygous (+/-) and null (-/-) tail DNAs were used as controls for the southern blot.

Figure 5.

Overexpression of Mdm4 suppresses p53 response after ionizing radiation (IR). (A) A time course of p53 and Mdm4 protein levels in spleens of 6 week-old female mice irradiated with 6 Gy. A tubulin antibody was used as control. (B) Activation of p53 transcriptional targets *Mdm2*, *p21*, and *Puma* as measured by RT-qPCR in splenocytes from WT and *Mdm4^{Tg15}* mice after 6 Gy IR. Three mice were examined at each time point. h, hours.

Table 1*Mdm4* expression levels*

Tissues	<i>Mdm4</i>^{Tg1}	<i>Mdm4</i>^{Tg6}	<i>Mdm4</i>^{Tg15}
Spleen	1.7±1.0	2.9±0.6	6.7±2.4
Thymus	1.5±0.4	2.6±0.6	3.1±1.1
Muscle	6.5±0.1	56.3±12.8	23.1±7.4
Liver	1.1±0.2	1.2±0.1	8.7±2.9
Intestine	2.1±0.1	8.4±1.7	16.8±4.2
Kidney	0.8±0.1	1.2±0.1	3.3±0.6
Heart	6.5±0.1	29.6±1.5	18.0±4.4
Lung	0.8±0.1	2.1±0.1	10.0±2.3

* The expression levels were compared to tissues from wild type littermates as fold change determined by RT-qPCR

Table 2 Tumor Spectra in *Mdm4* transgenic mice

Tumor Types	<i>Mdm4</i> ^{Tg1} (N=24)	<i>p53</i> ^{+/-} (N=44)	<i>Mdm4</i> ^{Tg1} <i>p53</i> ^{+/-} (N=44)	<i>Mdm4</i> ^{Tg15} (N=13)
Sarcoma	9 (37%)	30 (68%)	28 (64%)	4 (31%)
Hemangiosarcoma	4	3	1	0
Osteosarcoma	1 ¹	15	18	0
Sarcoma, NOS ²	4	12	7	3 ³
Malignant peripheral Nerve sheath tumor	0	0	1	1
Neurofibrosarcoma			1	
Carcinoma	3 (13%)	2 (5%)	5 (11%)	1 (7%)
Adenocarcinoma	2	1	4	0
Spindle Cell Carcinoma	0	1	0	0
Squamous Cell Carcinoma	1	0	1	0
Hepatocellular Carcinoma	0	0	0	1
Lymphoma	8 (33%)	10 (23%)	5 (11%)	4 (31%)
Histiocytic Sarcoma ⁴	4 (17%) ⁵	2 (5%)	6 (14%)	4 (31%) ⁵

¹ This Osteosarcoma had metastasis² Not Otherwise Specified³ 1 of 3 Sarcomas NOS had metastasis⁴ Macrophage origin⁵ 2 of 4 Histiocytic Sarcomas had metastasis